Published in final edited form as:

Org Lett. 2008 October 16; 10(20): 4449–4452. doi:10.1021/ol8016947.

Stereospecific Total Synthesis of Somocystinamide A

Takashi L. Suyama and William H. Gerwick*

Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093

Abstract

The first total synthesis of somocystinamide A, a disulfide dimer with extremely labile enamide functional groups, was accomplished in a concise and stereospecific manner. Somocystinamide A is reported to possess exceptionally potent anti-angiogenic and tumoricidal activities. The current work should enable further pharmacological investigation of this important natural product.

Marine cyanobacteria are a rich source of biomedically relevant secondary metabolites that are of unique molecular architecture.¹ In line with this theme, somocystinamide A (**1**) was isolated from a mixed assemblage of *Schizothrix* and *Lyngbya* and shown to possess remarkable biological properties.^{2,3} Initially, **1** only showed moderate activity against mouse neuroblastoma cells (Neuro-2a).³ In subsequent studies, however, its IC₅₀ against human umbilical vein endothelial cells (HUVECs) was found to be 500 fM.² This astonishing *in vitro* finding was verified in zebra fish wherein antiangiogenic effects were observed at 80 nM media concentration. Despite this potency, **1** was shown to have no observable adverse effects on zebra fish even at 30 μM. In addition, **1** was shown to trigger apoptosis in tumor cells via caspase-8 activation.² This activity profile supports the development of **1**, or analogs thereof, for potential use in cancer treatment.

Biosynthetically, somocystinamide A appears to be assembled through alternating NRPS-PKS elements with a unique termination of a PKS unit via decarboxylation and dehydration to furnish the terminal olefin as seen in curacin A.⁴ Methylation of the enamide using S-adenosyl methionine, a signature decoration in marine cyano-bacterial natural products,⁵ produces the tertiary enamide. Secondary enamides have been observed in many natural products and their preparation has been studied extensively in recent years.⁶ Tertiary enamides, however, are encountered very rarely in natural products and as such, the strategies for their preparation are relatively undeveloped and scarce.^{6,7} Furthermore, the presence of the disulfide group in **1** requires great care and consideration during the course of synthesis.⁸ For example, synthetic investigation of epidithiapiperazinedione natural products (such as **2**) has met with much difficulty in the installation of the disulfide.^{8,9} To date, only one complete total synthesis of a compound of this class has been reported.¹⁰

wgerwick@ucsd.edu.

Supporting Information Available: Experimental procedures, compound characterization, and ¹H and ¹³C NMR spectra for compounds **6**, **8**, **13–15**, **17**, and **1**. Video and pictures of somocystinamide A and control treated brine shrimp. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Another case in point is psammaplin A (**3**); in all three of the published syntheses of **3**, the sulfur atoms were introduced as a disulfide in the final step so as to avoid side reactions.¹¹

It was envisioned in the synthesis of **1** that the key carbon-carbon connection at the internal olefin would be made by olefin cross metathesis using a ruthenium catalyst.¹² Accordingly, terminal olefin **6** was prepared from the known aldehyde **5**¹³ via a Wittig reaction.¹⁴ Thiazolidine was chosen as the protecting group for the thiol of **4** because of its relative stability and its tandem protection of the carbamate proton.

Screening of commercially available ruthenium catalysts revealed that the second generation Hoveyda-Grubbs catalyst (**11**) was optimal (table 1).^{12c} Furthermore, this reaction was optimized for multi-gram scale by adjusting the concentration and number of equivalents of **7**. Good stereoselectivity was observed in all cases (e.g. *trans* : *cis* = 18:1, entry 8). Minimizing the amount of **7** facilitated the purification process because the major side product of the reaction, dimer **12**, closely eluted with the desired product **8** during chromatography. In line with recent reports that some ruthenium catalysts are more functional group-tolerant than initially suspected,¹⁵ alkyl sulfides are apparently very well tolerated by **11**, but not by **9**, suggesting that there may be competition between tri-cyclohexylphosphine and the sulfide **6** for binding as a ligand on ruthenium.¹⁶

The methyl ester **8** was hydrolyzed to obtain the carboxylic acid **13** in order to avoid undesired reduction to the primary alcohol. Afterward, the thiol and the carbamate of **13** were reductively deprotected by sodium in liquid ammonia (scheme 2).^{13a} Re-protection of the carboxylic acid as a methyl ester, deprotection of the amine, and acetylation yielded **14** in a good yield. Simultaneous basic hydrolysis of the methyl ester and the thioacetate in the presence of O₂ cleanly caused dimerization to the disulfide in one pot to give **15**. However, attempts to effect the dimerization by conventional means, such as treatment with I₂, did not give good yields.¹⁷

With **15** (named “somocystinoic acid”) in hand, various conditions were investigated to couple the *in-situ* generated imine **16** to the corresponding di-acyl chloride **20**, the formation of which was verified by the reaction with methylamine to produce **17**. In most cases, the starting material decomposed while in some cases a trace amount of **1** was observed. This result was curious because there are reports of synthesis of simple enamides via acylation of the corresponding acid chloride with imine.^{7,18} It is possible that the putative acyl iminium ion intermediate **21** is intercepted via an intramolecular reaction due to its dimeric nature (scheme 3).¹⁸ In support of this hypothesis, only tautomer **16** and not **19** was observed by ¹H and ¹³C NMR in CD₂Cl₂.¹⁹

We then turned our attention to the recently developed Cu-mediated vinylation reaction.⁶ It has been reported, although with little experimental evidence, that this approach is inapplicable to acyclic secondary amides.^{6b,d,f}

Therefore, coupling between a simple amide **23** and a commercially available vinyl bromide **24** was investigated, but found ineffective, giving support to these earlier reports.

Observation that the hydrolytic decomposition of **1** to **17** occurs with relatively low activation energy³ inspired us to carry out the opposite reaction,²⁰ specifically condensation of the aldehyde **18**²¹ with **17**. A Soxhlet extraction apparatus was found to be a convenient vessel for small scale reactions and allowed the use of solvents heavier than water.²² Observing that the putative intermediate **21** did not yield **1**, we hypothesized that the E1 pathway was not viable (scheme 3). In support of this hypothesis, use of a more polar solvent, THF, decreased the yield in comparison to 1,2-dichloroethane, a less polar

solvent.²³ The best result was obtained when TsOH was used as the catalyst, which gave a 41% yield. Further investigation of this reaction is underway on model systems.

The analytical data (¹H and ¹³C NMR, MS, UV, IR and optical rotation) for synthetic **1** were essentially identical to those for natural somocystinamide A,²⁴ thus confirming the originally assigned structure.³ The bioactivity of the synthetic product **1** was evaluated in the murine Neuro-2a cancer cell line, but its activity was highly variable,²⁵ possibly due to the unusual solubility properties of **1**, or to factors which we do not currently understand. We also tested synthetic **1** in the brine shrimp toxicity model²⁶ and observed significantly impaired motility in treated (at 1, 10 and 100 µg/mL) versus control shrimps (DMSO). We also noted a much decreased quantity of intestinal contents in the treated group. These observations underscore the value of a synthetic supply of somocystinamide A for it is clear that it possesses biological properties not yet understood.

In conclusion, the first total synthesis of somocystinamide A was achieved despite the presence of two quite challenging functional groups in the molecule. The current synthesis is fairly robust for all steps but the last two such that >1 g of **15** has been prepared smoothly, and scale-up necessary for *in vivo* testing of this biomedically exciting compound should now be possible. However, our work demonstrates the need for a more robust reaction to prepare tertiary enamides, a development which would open the door for synthesis of other natural products possessing this functional group, such as the laingolides.²⁷

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

TLS thanks D. Carson and the Moores Cancer Center for a student fellowship. Funding is acknowledged from NIH grant NS 053398. We thank J. Wingerd at SIO/UCSD for the Neuro-2a assay and Y. Su at UCSD for the mass spectroscopic analyses. We thank K. Schwartz at Oregon State University for suggesting the use of a Soxhlet extractor.

References

1. Gerwick, WH.; Tan, LT.; Sitachitta, N. The Alkaloids. Cordell, GA., editor. Vol. 57. Academic Press; San Diego, CA: 2001. p. 75-184.
2. Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, Klemke RL, Gerwick WH, Carson DA, Stupack DG. Proc Nat Acad Sci. 2008; 105:2313–2318. [PubMed: 18268346]
3. Nogle LM, Gerwick WH. Org Lett. 2002; 4:1095–1098. [PubMed: 11922791]
4. Moore BS. Nat Prod Rep. 2005; 22:580–593. [PubMed: 16193157]
5. Chang Z, Sitachitta N, Rossi J, Roberts MA, Flatt PM, Jia J, Sherman DH, Gerwick WH. J Nat Prod. 2004; 67:1356–1367. [PubMed: 15332855]
6. (a) Tracey MR, Hsung RP, Antoline J, Kurtz KC, Shen L, Slafer BW, Zhang Y. Science of Synthesis. 2005; 21:387–475. (b) Jiang L, Job GE, Klapars A, Buchwald SL. Org Lett. 2003; 5:3667–3669. [PubMed: 14507200] (c) Coleman RS, Liu P. Org Lett. 2004; 6:577–580. [PubMed: 14961627] (d) Dehli JR, Legros J, Bolm C. Chem Comm. 2005:973–986. [PubMed: 15719090] (e) Pan X, Cai Q, Ma D. Org Lett. 2004; 6:1809–1812. [PubMed: 15151420] (f) Han C, Shen R, Su S, Porco JA Jr. Org Lett. 2004; 6:27–30. [PubMed: 14703342]
7. (a) Cook GR, Stille JR. Tetrahedron. 1994; 50:4105–4124. (b) Gangadasu B, Narender P, Kumar SB, Ravinder M, Rao BA, Ramesh C, Raju BC, Rao VJ. Tetrahedron. 2006; 62:8398–8403. (c) Cook GR, Barta NS, Stille JR. J Org Chem. 1992; 57:461–467. (d) Couture A, Dubiez R, Lablache-Combier A. J Org Chem. 1984; 49:714–717. (e) Pattenden G, Ashweek NJ, Baker-Glenn CAG, Kempson J, Walker GM, Yee JGK. Org Biomol Chem. 2008; 6:1478–1497. [PubMed: 18385855] (f) Morales O, Seide W, Watson SE. Synth Comm. 2006; 36:965–973.

8. Overman LE, Sato T. *Org Lett.* 2007; 9:5267–5270. [PubMed: 18001051]
9. Middleton MD, Peppers BP, Diver ST. *Tetrahedron.* 2006; 62:10528–10540.
10. Fukuyama T, Nakatsuka S, Kishi Y. *Tetrahedron.* 1981; 37:2045–2078.
11. (a) Nicolaou KC, Hughes R, Pfefferkorn JA, Barluenga S, Roecker AJ. *Chem Eur J.* 2001; 7:4280–4295. [PubMed: 11686609] (b) Hoshino O, Murakata M, Yamada K. *Bioorg Med Chem Lett.* 1992; 2:1561–1562. (c) Coleman RS, Liu P. *Org Lett.* 2004; 6:577–580. [PubMed: 14961627]
12. (a) Scholl M, Ding S, Lee CW, Grubbs RH. *Org Lett.* 1999; 1:953–956. [PubMed: 10823227] (b) Nicolaou KC, Bulger PG, Sarlah D. *Angew Chem Int Ed.* 2005; 44:4490–4527. (c) Garber SB, Kingsbury JS, Gray BL, Hoveyda AH. *J Am Chem Soc.* 2000; 122:8168–8179.
13. Deroose FD, De Clercq PJ. *J Org Chem.* 1995; 60:321–330. (b) Chavan SP, Chittiboyina AG, Ramakrishna G, Tejawani RB, Ravindranathan T, Kamat SK, Rai B, Sivadasan L, Balakrishnan K, Ramalingam S, Deshpande VH. *Tetrahedron.* 2005; 61:9273–9280.
14. Rh-catalyzed methylenation with TMSCHN₂ gave poor results. (a) Wittig G, Schöllkopf U. *Ber.* 1954; 87:1318. (b) Lebel H, Paquet V. *J Am Chem Soc.* 2004; 126:320–328. [PubMed: 14709098]
15. (a) Compain P. *Adv Synth Catal.* 2007; 349:1829–1846. (b) Vernall AJ, Abell AD. *Aldrichimica Acta.* 2003; 36:93–105. (c) Suyama TL, Gerwick WH. *Org Lett.* 2006; 8:4541–4543. [PubMed: 16986945]
16. To our knowledge, this is the first example of a successful cross metathesis of an alkyl sulfide substrate by ruthenium carbene catalysis.
17. Atmospheric air as oxidant only worked for small scale reactions (*ca.* 10 mg). Larger scale reactions were run with bubbling O₂ (see experimental). For I₂ examples, see: Bourles E, Alves de Sousa R, Galardon E, Selkti M, Tomas A, Artaud I. *Tetrahedron.* 2007; 63:2466–2471.
18. The acetamide, disulfide, or already formed enamide of the other half of the dimeric intermediate may act as nucleophiles to attack the iminium ion. For examples of nucleophilic additions to iminium ions, see: Moonen K, Stevens CV. *Synthesis.* 2005; 20:3603–3612.
19. In separate studies, reaction of **16** with simple unfunctionalized acid chlorides formed enamides, thus indicating the presence of an acyliminium ion intermediate like **21**. Because **19** was not observed by NMR, an acylenaminium Intermediate is not likely involved.
20. In reference 3 it was found that **1** decomposed after a few days in CDCl₃ due to the residual acid and water present in this solvent.
21. Griffith GA, Percy JM, Pintat S, Smith CA, Spencer N, Uneyama E. *Org Biomol Chem.* 2005; 3:2701–2712. [PubMed: 16032348]
22. Instead of a thimble, glass wool and molecular sieves were used to capture any moisture distilled as an azeotrope.
23. (a) Saunders WH Jr. *Acc Chem Res.* 1976; 9:19–25. (b) Carey, FA.; Sundberg, RJ. *Advanced Organic Chemistry Part A.* 4. Kluwer Academic / Pleunum Publishers; New York: 2000. p. 378–383.
24. The ¹H and ¹³C were identical between natural and synthetic samples except the shift of C-16 showed a 0.2 ppm downfield shift in the synthetic sample. The UV maximum for synthetic somocystinamide was at 234 nm while natural was reported at 241 nm, both samples in MeOH.
25. IC₅₀ against Neuro-2a cells, synthetic **1** = 0.2 to >10 μM; natural **1** = 1.8 μM (ref. 3).
26. Meyer BN, Ferrigni NR, Putnam LB, Jacobson LB, Nichols DE, McLaughlin JL. *Plant Medica.* 1982; 45:31–34.
27. (a) Klein D, Braekman J, Daloze D, Hoffman L, Demoulin V. *Tetrahedron Lett.* 1996; 37:7519–7520. (b) Klein D, Braekman J, Daloze D, Hoffman L, Castillo G, Demoulin V. *J Nat Prod.* 1999; 62:934–936. [PubMed: 10395526]

Figure 1.
Examples of disulfide-containing natural products.

Scheme 1.
Cross metathesis to **8**

Scheme 2.
Synthesis of disulfide **15** (somocystinoic acid)

Pathway A Pathway B

Scheme 3.
Possible mechanisms for enamide formation

Scheme 4.
Synthesis of somocystinamide A (**1**)

Table 1Olefin cross metathesis with various conditions to produce **8**

	catalyst	conc. ^a	ester ^b	yield of 8 ^c
1	9 , 20 mol %	0.04	7 , 10 equiv	0%
2	10 , 20 mol %	0.04	7 , 10 equiv	26% (na)
3	10 , 4 mol %	0.04	7 , 3 equiv	23% (57%)
4	11 , 5 mol %	0.03	7 , 3 equiv	81% (94%)
5	11 , 5 mol %	0.03	12 , 1.5 equiv	53% (55%)
6	11 , 2.5 mol %	0.03	7 , 3 equiv	44% (na)
7 ^d	11 , 5 mol %	0.04	7 , 3 equiv	73% (83%)
8 ^e	11 , 5 mol %	0.2	7 , 2.2 equiv	82% (82%)

^a Concentration of **6** (M);^b Equivalents of **7** or **12** with respect to **6**;^c Isolated yields. Yields in parentheses are based on recovered starting material;^d 3.2 g scale (ca. 10 times more than entries 1–6);^e 5.5 g scale.